Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.51 |
| ▸ | CTSK | P43235 | 3/20 | 0.51 |
| ▸ | CTSL | P07711 | 1/20 | 0.51 |
| ▸ | CTSS | P25774 | 1/20 | 0.51 |
| ▸ | TNF | P01375 | 1/20 | 0.49 |
| ▸ | MDM4 | O15151 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29480487 | 0.90 | CTSK (0.51) | HDAC1HDAC2CTSKCTSLCTSS | |
| SCHEMBL12677569 | 0.88 | MDM4 (0.49) | MDM4TP53CASP3KMT2A | |
| SCHEMBL29624621 | 0.88 | MDM4 (0.56) | TNFMDM4TP53CASP3 | |
| SCHEMBL29367497 | 0.88 | MDM4 (0.56) | TNFMDM4TP53CASP3 | |
| SCHEMBL29355082 | 0.88 | MDM4 (0.56) | TNFMDM4TP53CASP3 | |
| SCHEMBL598209 | 0.88 | MDM4 (0.56) | TNFMDM4TP53CASP3 | |
| SCHEMBL119565 | 0.88 | MDM4 (0.56) | TNFMDM4TP53CASP3 | |
| SCHEMBL119575 | 0.88 | MDM4 (0.56) | TNFMDM4TP53CASP3 | |
| SCHEMBL30802551 | 0.88 | MDM4 (0.56) | TNFMDM4TP53CASP3 | |
| SCHEMBL31385405 | 0.87 | MDM4 (0.47) | MDM4TP53CASP3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11583538-B2 | Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors | Venenum Biodesign, LLC (US) | 2023-02-21 | — | — | US | disclosed |
| WO-2022075974-A1 | CYCLIC TREX1 INHIBITORS | Venenum Biodesign, LLC (US) | 2022-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11583538-B2 | Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors | TMX1, P2RX1, TCOF1 | HDAC1 229/4885HDAC2 429/4885CTSK 4170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.